Dogwood Therapeutics, Inc. Operating Expenses
Dogwood Therapeutics, Inc. (DWTX) reported Operating Expenses of $14.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Dogwood Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $14.06M, a 258.48% increase year-over-year.
- Dogwood Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $5.08M, a 14.59% increase year-over-year.
- Dogwood Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $3.81M, a 49.53% decline year-over-year.
- Dogwood Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $15.81M, a 587.00% increase year-over-year.
- Dogwood Therapeutics, Inc. operating expenses for fiscal 2025 was $27.97M, a 128.74% increase from fiscal 2024.
- Dogwood Therapeutics, Inc. operating expenses for fiscal 2024 was $12.23M, a 124.48% increase from fiscal 2023.
- Dogwood Therapeutics, Inc. operating expenses for fiscal 2023 was $5.45M, a 55.77% decline from fiscal 2022.
- Dogwood Therapeutics, Inc. operating expenses for fiscal 2022 was $12.32M, a 21.26% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.06M 10-Q · filed 2026-08-14 | $19.14M 10-Q · filed 2026-08-14 | $22.95M derived: sum of 3 quarters · filed 2026-08-14 | $38.76M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.08M 10-Q · filed 2026-05-15 | $8.88M derived: sum of 2 quarters · filed 2026-05-15 | $24.69M derived: sum of 3 quarters · filed 2026-05-15 | $28.61M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $19.62M derived: sum of 2 quarters · filed 2026-03-18 | $23.54M derived: sum of 3 quarters · filed 2026-08-14 | $27.97M 10-K · filed 2026-03-18 |
| 2025-09-30 | $15.81M 10-Q · filed 2025-11-07 | $19.73M derived: sum of 2 quarters · filed 2026-08-14 | $24.16M 10-Q · filed 2025-11-07 | $31.70M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.92M 10-Q · filed 2026-08-14 | $8.35M 10-Q · filed 2026-08-14 | $15.90M derived: sum of 3 quarters · filed 2026-08-14 | $18.20M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $4.43M 10-Q · filed 2026-05-15 | $11.97M derived: sum of 2 quarters · filed 2026-05-15 | $14.27M derived: sum of 3 quarters · filed 2026-05-15 | $15.34M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $9.84M derived: sum of 2 quarters · filed 2026-03-18 | $10.91M derived: sum of 3 quarters · filed 2026-03-18 | $12.23M 10-K · filed 2026-03-18 |
| 2024-09-30 | $2.30M 10-Q · filed 2025-11-07 | $3.37M derived: sum of 2 quarters · filed 2025-11-07 | $4.69M 10-Q · filed 2025-11-07 | $5.82M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $1.07M 10-Q · filed 2025-08-13 | $2.38M 10-Q · filed 2025-08-13 | $3.52M derived: sum of 3 quarters · filed 2025-08-13 | $4.80M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.31M 10-Q · filed 2025-05-09 | $2.45M derived: sum of 2 quarters · filed 2025-05-09 | $3.73M derived: sum of 3 quarters · filed 2025-05-09 | $5.20M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.41M derived: sum of 2 quarters · filed 2025-03-31 | $3.89M derived: sum of 3 quarters · filed 2025-03-31 | $5.45M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.27M 10-Q · filed 2024-11-08 | $2.75M derived: sum of 2 quarters · filed 2024-11-08 | $4.31M 10-Q · filed 2024-11-08 | $6.40M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $1.48M 10-Q · filed 2024-08-09 | $3.03M 10-Q · filed 2024-08-09 | $5.12M derived: sum of 3 quarters · filed 2024-08-09 | $7.72M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $1.56M 10-Q · filed 2024-05-10 | $3.65M derived: sum of 2 quarters · filed 2024-05-10 | $6.24M derived: sum of 3 quarters · filed 2024-05-10 | $9.91M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $2.09M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-08 | $4.68M derived: sum of 2 quarters · filed 2024-03-08 | $8.35M derived: sum of 3 quarters · filed 2024-03-08 | $12.32M 10-K/A · filed 2024-03-08 |
| 2022-09-30 | $2.59M 10-Q · filed 2023-11-13 | $6.26M derived: sum of 2 quarters · filed 2023-11-13 | $10.23M 10-Q · filed 2023-11-13 | $14.41M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $3.67M 10-Q · filed 2023-08-11 | $7.63M 10-Q · filed 2023-08-11 | $11.82M derived: sum of 3 quarters · filed 2023-08-11 | $15.93M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $3.96M 10-Q · filed 2023-05-12 | $8.15M derived: sum of 2 quarters · filed 2023-05-12 | $12.26M derived: sum of 3 quarters · filed 2023-05-12 | $16.54M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $8.30M derived: sum of 2 quarters · filed 2023-03-14 | $12.58M derived: sum of 3 quarters · filed 2023-03-14 | $15.64M 10-K · filed 2023-03-14 |
| 2021-09-30 | $4.11M 10-Q · filed 2022-11-14 | $8.40M derived: sum of 2 quarters · filed 2022-11-14 | $11.45M 10-Q · filed 2022-11-14 | $17.88M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $4.28M 10-Q · filed 2022-08-12 | $7.34M 10-Q · filed 2022-08-12 | $13.76M derived: sum of 3 quarters · filed 2022-08-12 | $16.43M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $3.06M 10-Q · filed 2022-05-13 | $9.48M derived: sum of 2 quarters · filed 2022-05-13 | $12.14M derived: sum of 3 quarters · filed 2022-05-13 | $12.68M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $6.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $9.08M derived: sum of 2 quarters · filed 2022-03-18 | $9.62M derived: sum of 3 quarters · filed 2022-03-18 | $10.01M 10-K · filed 2022-03-18 |
| 2020-09-30 | $2.66M 10-Q · filed 2021-11-12 | $3.20M derived: sum of 2 quarters · filed 2021-11-12 | $3.58M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $538.38K 10-Q · filed 2021-08-13 | $920.93K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $382.55K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |